左乙拉西坦治疗系统性红斑狼疮继发部分性癫痫疗效及安全性分析

Efficacy and safety of levetiracetam in treatment of systemic lupus erythematosus secondary partial epilepsy

目的探讨左乙拉西坦在治疗系统性红斑狼疮(SLE)继发部分性癫痫中的疗效及安全性。方法选取自2009年1月至2015年12月解放军陆军总医院收治的SLE继发癫痫患者62例,按随机数字表法分为对照组(31例)和观察组(31例)。对照组患者给予口服卡马西平片,观察组患者给予左乙拉西坦片,比较左乙拉西坦和卡马西平治疗癫痫的有效性及不良反应的发生率。结果观察组总有效率高于对照组,不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论左乙拉西坦治疗SLE继发部分性癫痫发作疗效良好,且安全性高。

Objective To explore the safety and efficacy of levetiracetam in treatment of systemic lupus erythematosus（ SLE） secondary partial epilepsy. Methods A retrospective study was performed on 62 patients with SLE secondary partial epilepsy in the General Hospital of Beijing Military Command from January 2009 to December 2015. Accordance to the random number table,patients were divided into the control group（ n = 31） and the observation group（ n = 31）. Patients in the control group were administrated carbamazepine and the others in the observation group were administrated levetiracetam. The efficacy in the treatment of secondary partial epilepsy and adversed reactions in the two groups of patients were observed and compared. Results In the observation group,the total effective rate was higher and the adverse reactions were less than those in the control group. The difference was statistically significant（ P〈0. 05）. Conclusion Levetiracetam in treatment of SLE secondary partial epilepsy has a good curative effect and high safety.